Choroideremia Treatment Market Size

  • Report ID: 5519
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Choroideremia Treatment Market size was over USD 9.43 billion in 2024 and is poised to exceed USD 17.35 billion by 2037, witnessing over 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of choroideremia treatment is evaluated at USD 9.81 billion.

The growth of this market can be ascribed to the increasing prevalence of choroideremia all across the globe. 1 in 50,000 to 100,000 people in the United States has choroideremia according to the Centers for Disease Control and Prevention.

Due to the delay in diagnosis and treatment of patients with choroideremia, COVID-19 is likely to have an important effect on the therapeutic market for choroideremia. Anyhow, the result will be short-term and post-COVID-19 pandemic, the choroideremia treatment market will show a significant surge owing to an increase in treatment adoption.


Choroideremia Treatment Market Overviews

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of choroideremia treatment is evaluated at USD 9.81 billion.

The choroideremia treatment market size was over USD 9.43 billion in 2024 and is poised to exceed USD 17.35 billion by 2037, witnessing over 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of choroideremia and growing advancement in medical technology will boost the market growth.

North America industry is set to hold largest revenue share of 35% by 2037, due to rising substantial innovation in healthcare infrastructure in the region.

The major players in the market are Biogen, Copernicus Therapeutics, Inc., 4D Molecular Therapeutics, Wize Pharma Inc., Retina Implant AG, Hoffmann-La Roche Ltd, and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos